{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:43:16Z","timestamp":1792197796718,"version":"4.4.0"},"reference-count":50,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T00:00:00Z","timestamp":1469145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p>Gouty arthritis is one of the most common rheumatic diseases. The clinical burden of gouty arthritis has historically been well recognized; however, gout is often misdiagnosed and mismanaged. The prevalence of gout is rising and is likely attributed to several factors including increased incidence of comorbidities, lifestyle factors, and increased use of causative medications. With the increasing prevalence, there have been several innovations and evidence\u2010based updates related to the diagnosis and management of gout. Acute gouty arthritis should be treated with nonsteroidal antiinflammatory drugs (<jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s), colchicine, or corticosteroids, or a combination of two agents. Xanthine oxidase inhibitor therapy remains the consensus first\u2010line treatment option for the prevention of recurrent gout. Add\u2010on therapies that reduce serum urate concentration include traditional uricosuric agents and a novel uric acid reabsorption inhibitor. Prophylaxis of acute gout with <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s, colchicine, or corticosteroids is universally recommended when initiating any urate\u2010lowering therapy in order to prevent acute gouty arthritis for a period of at least 6 months. In this review, we discuss the epidemiology and risk factors for gouty arthritis and evaluate diagnostic strategies and therapeutic regimens for the management of gout, including a new drug approval.<\/jats:p>","DOI":"10.1002\/phar.1788","type":"journal-article","created":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T09:32:48Z","timestamp":1466242368000},"page":"906-922","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Gouty Arthritis: A Review of Acute Management and Prevention"],"prefix":"10.1002","volume":"36","author":[{"given":"Liza","family":"Wilson","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado"},{"name":"Department of Family Medicine University of Colorado School of Medicine Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Saseen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado"},{"name":"Department of Family Medicine University of Colorado School of Medicine Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1906"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21773"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30520"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4370"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2012.00674.x"},{"key":"e_1_2_8_8_1","first-page":"1505","volume-title":"Pharmacotherapy: a pathophysiologic approach","author":"Fravel MA","year":"2014"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60883-7"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380508"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1001124"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61343-4"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21242"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16000-5"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1638"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035700"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055251"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.196"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091385"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510280064034"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1742395310378761"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201676"},{"key":"e_1_2_8_24_1","first-page":"331","article-title":"Local ice therapy during bouts of acute gouty arthritis","volume":"29","author":"Schlesinger N","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1987.tb01232.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1003126"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27327"},{"key":"e_1_2_8_28_1","unstructured":"2012 Takeda Pharmaceuticals America Inc. Deerfield IL"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2143"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3297"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes183"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12413"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22336"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201676"},{"key":"e_1_2_8_35_1","unstructured":"Product Information: allopurinol oral tablet allopurinol oral tablet.Jacksonville FL:Ranbaxy Pharmaceuticals Inc. (per DailyMed) 2011."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2978"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091462"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34488"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-009-0019-z"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380240052027"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328330a3b8"},{"key":"e_1_2_8_42_1","unstructured":"Uloric [package insert].Deerfield IL:Takeda Pharmaceuticals America Inc. March2013."},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_8_44_1","unstructured":"Product Information: probenecid oral tablets probenecid oral tablets.New Castle DE:Marlex Pharmaceuticals Inc.(per DailyMed) 2012."},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/cp.1999.v66.99709"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00739.x"},{"key":"e_1_2_8_47_1","unstructured":"Product Information: KRYSTEXXA injection for IV infusion pegloticase injection for IV infusion.East Brunswick NJ:Savient Pharmaceuticals Inc 2010."},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1169"},{"key":"e_1_2_8_49_1","unstructured":"Product Information: Zurampic oral tablet lesinurad oral tablet.Wilmington DE:AstraZeneca Pharmaceuticals LP 2015."},{"key":"e_1_2_8_50_1","article-title":"Lesinurad, a novel selective uric acid reabsorption inhibitor, in two phase III clinical trials: combination study of lesinurad in allopurinol standard of care inadequate responders (CLEAR 1 and 2) [abstract]","author":"Saag KG","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"e_1_2_8_51_1","article-title":"Lesinurad, a novel selective uric acid reabsorption inhibitor, in combination with Febuxostat, in Patients with Tophaceous gout [abstract]","volume":"67","author":"Dalbeth N","year":"2015","journal-title":"Arthritis Rheumatol"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1788","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:58:47Z","timestamp":1761058727000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,22]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1002\/phar.1788"],"URL":"https:\/\/doi.org\/10.1002\/phar.1788","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,22]]},"assertion":[{"value":"2016-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}